Tag: conditional marketing authorization

Conditional Marketing Authorization Pathways for Rare Disease Therapies

August 17, 2025

Conditional Marketing Authorization Pathways for Rare Disease Therapies Accelerating Rare Disease Access with Conditional Marketing Authorizations What Is Conditional Marketing Authorization (CMA)? Conditional Marketing Authorization (CMA) is a regulatory pathway in the European Union that allows for the early approval of medicines that address serious or life-threatening diseases, especially where there is an unmet medical…

Rare and Orphan Disease Trials, Regulatory Frameworks

How EMA’s PRIME Scheme Accelerates Rare Disease Therapies

August 14, 2025

digi

How EMA’s PRIME Scheme Accelerates Rare Disease Therapies Accelerating Rare Disease Treatments Through the EMA PRIME Scheme Introduction to the PRIME Scheme The Priority Medicines (PRIME) scheme was launched by the European Medicines Agency (EMA) in 2016 to enhance support for the development of medicines targeting unmet medical needs. PRIME provides early and proactive regulatory…

Rare and Orphan Disease Trials, Regulatory Frameworks

Conditional Approval Pathways for Unmet Needs

August 6, 2025

digi

Conditional Approval Pathways for Unmet Needs How Conditional Approvals Accelerate Therapies for Unmet Rare Disease Needs Understanding the Concept of Conditional Approval In the context of rare and life-threatening diseases, traditional drug approval processes—requiring full clinical trial data—may delay patient access to critical therapies. Regulatory agencies such as the European Medicines Agency (EMA) and the…

Rare and Orphan Disease Trials, Regulatory Incentives

Accelerated Pathways for Vaccine Approval

August 3, 2025

digi

Accelerated Pathways for Vaccine Approval Navigating Accelerated Vaccine Approval Pathways Without Compromising Quality Why Accelerated Pathways Exist—and When They’re Appropriate Accelerated pathways exist to address serious, life-threatening, or public health emergency conditions where waiting for long, traditional development cycles would result in preventable morbidity and mortality. For vaccines, acceleration is justified when there is a…

Phase I–IV Vaccine Trials, Vaccine Clinical Trials